4th Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference

Synopsis

Defects in DNA damage repair and checkpoint control are underlying mechanisms driving tumorigenesis, since they allow for the accumulation of genetic alternations. Indeed, defects associated with these pathways are the underlying cause of several human cancer-prone syndromes. On the other hand, defects in DNA repair and checkpoint control create vulnerabilities in cancer cells that can be targeted by DNA damaging agents and inhibitors that disrupt checkpoint pathways. More recently, defective DNA repair and checkpoint regulation have been shown to influence R-loop formation, replication fork stability, and innate immunity. These new findings not only reveal additional mechanisms contributing to tumorigenesis, but also provide new targets for cancer therapy. This conference will focus on exploring these vulnerabilities, taking advantage of the synthetic lethality concept, and targeting specific DNA repair and checkpoint pathways for cancer therapy, either alone or in combination with chemotherapy, radiation therapy, targeted therapy, and immunotherapy. This conference will bring together basic, translational and clinical investigators to discuss current and future directions, opportunities and obstacles to the development of these anti-cancer modalities and how to best translate these concepts to clinical practice.

Click here for the PDF description of the event

Key Sessions

• Recent advances in the field of DNA repair, cell cycle checkpoint control, genome maintenance, and innate immunity
• Radiation therapy and immune response
• Novel targets in DNA repair and checkpoint pathways
• Explore synthetic lethality and combination therapy for cancer treatment
• Evaluate the therapeutic potential of new anti-cancer modalities and combinations
• Mechanisms underlying therapeutic resistance 

Confirmed Invited Speakers

Britt Adamson (Princeton University)

Jiri Bartek (Danish Cancer Society Research Center)

Sharon Cantor (University of Massachusetts)

Karlene Cimprich (Stanford University)

Elizabeth Christie (Peter MacCallum Cancer Centre)

Thanos Halazonetis (University of Geneva)

Maria Jasin (Memorial Sloan Kettering Cancer Center)

Jan Karlseder (The Salk Institute)

Chris Lord (Institute of Cancer Research)

Zhenkun Lou (Mayo Clinic)

Andre Nussenzweig (National Institutes of Health)

Mark O'Connor (AstraZeneca)

Helen Robinson (Artios)

Clare L. Scott (Walter and Eliza Hall Institute of Medical Research)

John Tainer (MD Anderson Cancer Center)

Steve West (Francis Crick Institute)

Shan Zha (Columbia University)

Lee Zou (Duke University)